Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions

Tissue Engineering - Part A

Volumn 20, Issue 15-16, 2014, Pages 2243-2252

  Van Beuningen, Henk M ^a   De Vries Van Melle, Marloes L ^b   Vitters, Elly L ^a   Schreurs, Wim ^a   Van Den Berg, Wim B ^a   Van Osch, Gerjo J V M ^b   Van Der Kraan, Peter M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE; COLLAGEN; DATA STORAGE EQUIPMENT; GLYCOPROTEINS; PELLETIZING; POLYMERASE CHAIN REACTION; STEM CELLS;

CARTILAGE FORMATION; CHONDROGENIC DIFFERENTIATION; HUMAN MESENCHYMAL STEM CELLS; HUMAN MESENCHYMAL STEM CELLS (HMSCS); MATRIX METALLOPROTEINASES; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTORS;

ENZYME INHIBITION;

AGGRECAN; AGGRECANASE 1; AGGRECANASE 2; COLLAGEN TYPE 2; COLLAGENASE 3; GLYCOSAMINOGLYCAN; INTERSTITIAL COLLAGENASE; MESSENGER RNA; OXOZEAENOL; PROTEIN SERINE THREONINE KINASE INHIBITOR; STROMELYSIN; TOFACITINIB; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; JANUS KINASE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; ZEARALENONE;

ADULT; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FETUS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIUM; ANTAGONISTS AND INHIBITORS; ARTICULAR CARTILAGE; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; TIME;

ADULT; CARTILAGE, ARTICULAR; CELL DIFFERENTIATION; CHONDROGENESIS; FETUS; HUMANS; JANUS KINASES; MAP KINASE KINASE KINASES; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; TIME FACTORS; ZEARALENONE;

EID: 84905570297     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2013.0553     Document Type: Article

References (41)

1. Yang, K.G., Saris, D.B., Verbout, A.J., Creemers, L.B., and Dhert, W.J. The effect of synovial fluid from injured knee joints on in vitro chondrogenesis. Tissue Eng 12, 2957, 2006.
2. Rodrigo, J.J., Steadman, J.R., Syftestad, G., Benton, H., and Silliman, J. Effects of human knee synovial fluid on chondrogenesis in vitro. Am J Knee Surg 8, 124, 1995.
3. Krüger, J.P., Endres, M., Neumann, K., Stuhlmüller, B., Morawietz, L., Häupl, T., and Kaps, C. Chondrogenic differentiation of human subchondral progenitor cells is affected by synovial fluid from donors with osteoarthritis or rheumatoid arthritis. J Orthop Surg Res 7, 10, 2012.
4. Heldens, G.T., Blaney Davidson, E.N., Vitters, E.L., Schreurs, B.W., Piek, E., van den Berg, W.B., and van der Kraan, P.M. Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells. Tissue Eng Part A 18, 45, 2012.
5. Sakurai, H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 33, 522, 2012.
6. Delaney, J.R., and Mlodzik, M. TGF-beta activated kinase-1: New insights into the diverse roles of TAK1 in development and immunity. Cell Cycle 5, 2852, 2006.
7. Ninomiya-Tsuji, J., Kishimoto, K., Hiyama, A., Inoue, J., Cao, Z., and Matsumoto, K. The kinase TAK1 can activate the NIKIkB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398, 252, 1999.
8. Sakurai, H., Miyoshi, H., Toriumi, W., and Sugita, T. Functional interactions of transforming growth factor bactivated kinase 1 with IkB kinases to stimulate NF-kB activation. J Biol Chem 274, 10641, 1999.
9. Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415, 1994.
10. Schindler, C., and Darnell, J.E., Jr. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64, 621, 1995.
11. Kisseleva, T., Bhattacharya, S., Braunstein, J., and Schindler, C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1, 2002.
12. Murray, P.J. The JAK-STAT signaling pathway: Input and output integration. J Immunol 178, 2623, 2007.
13. O'Sullivan, L.A., Liongue, C., Lewis, R.S., Stephenson, S.E., and Ward, A.C. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 44, 2497, 2007.
14. Yoshimura, A., Naka, T., and Kubo, M. SOCS proteins, cytokine signaling and immune regulation. Nat Rev Immunol 7, 454, 2007.
15. Aaronson, D.S., and Horvath, C.M. A road map for those who don't know JAK-STAT. Science 296, 1653, 2002.
16. Ghoreschi, K., Jesson, M.I., Li, X., Lee, J.L., Ghosh, S., Alsup, J.W.,Warner, J.D., Tanaka, M., Steward-Tharp, S.M., Gadina, M.,Thomas,C.J., Minnerly, J.C., Storer, C.E.,LaBranche,T.P., Radi, Z.A., Dowty, M.E., Head, R.D., Meyer, D.M., Kishore, N., and O'Shea, J.J.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186, 4234, 2011.
17. Meyer, D.M., Jesson, M.I., Li, X., Elrick, M.M., Funckes-Shippy, C.L., Warner, J.D., Gross, C.J., Dowty, M.E., Ramaiah, S.K., Hirsch, J.L., Saabye, M.J., Barks, J.L., Kishore, N., and Morris, D.L. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7, 41, 2010.
18. van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M.H., Cohen, S., Nash, P., Song, Y.W., Tegzová, D., Wyman, B.T., Gruben, D., Benda, B., Wallenstein, G., Krishnaswami, S., Zwillich, S.H., Bradley, J.D., Connell, C.A., and the ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 559, 2013.
19. Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S.H., Koncz, T., Soma, K., Bradley, J., Mebus, C., and the ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 381, 451, 2013.
20. Kurth, T., Hedbom, E., Shintani, N., Sugimoto, M., Chen, F.H., Haspl, M., Martinovic, S., and Hunziker, E.B. Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthritis Cartilage 15, 1178, 2007.
21. Farndale, R.W., Buttle, D.J., and Barrett, A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883, 173, 1986.
22. Beier, F., and Loeser, R.F. Biology and pathology of Rho GTPase, PI-3 kinase-Akt and MAP kinase signaling pathways in chondrocytes. J Cell Biochem 110, 573, 2010.
23. Scharstul, A., Diepens, R., Lensen, J., Vitters, E., van Beuningen, H., van der Kraan, P., and van den Berg, W.B. Adenoviral overexpression of Smad-7 and Smad-6 differentially regulates TGF-beta-mediated chondrocyte proliferation and proteoglycan synthesis. Osteoarthritis Cartilage 11, 773, 2003.
24. Hoffmann, A., Preobrazhenska, O., Wodarczyk, C., Medler, Y., Winkel, A., Shahab, S., Huylebroeck, D., Gross, G., and Verschueren, K. Transforming growth factorb-Activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. J Biol Chem 280, 27271, 2005.
25. Yumoto, K., Thomas, P.S., Lane, J., Matsuzaki, K., Inagaki, M., Ninomiya-Tsuji, J., Scott, G.J., Ray, M.K., Ishii, M., Maxson, R., Mishina, Y., and Kaartinen, V. TGFb-Activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells. J Biol Chem 288, 13467, 2013.
26. Hanafusa, H., Ninomiya-Tsuji, J., Masuyama, N., Nishita, M., Fujisawa, J., Shibuya, H., Matsumoto, K., and Nishida, E. Involvement of the p38 mitogen-Activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 274, 27161, 1999.
27. Nakamura, K., Shirai, T., Morishita, S., Uchida, S., Saeki-Miura, K., and Makishima, F. p38 mitogen-Activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Exp Cell Res 250, 351, 1999.
28. Jin, E.J., Lee, S.Y., Choi, Y.A., Jung, J.C., Bang, O.S., and Kang, S.S. BMP-2-enhanced chondrogenesis involves p38 MAPK-mediated down-regulation of Wnt-7a pathway. Mol Cells 22, 353, 2006.
29. Derynck, R., and Zhang, Y.E. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 425, 577, 2003.
30. Tuli, R., Tuli, S., Nandi, S., Huang, X., Paul, A., Manner, P.A., Hozack, W.J., Danielson, K.G., Hall, D.J., and Tuan, R.S. Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-Activated protein kinase and Wnt signaling cross-Talk. J Biol Chem 278, 41227, 2003.
31. Zuzarte-Luis, V., Montero, J.A., Rodriguez-Léon, J., Merino, R., Rodriguez-Rey, J.C., and Hurlé, J.M. A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev Biol 272, 39, 2004.
32. Gunnell, L.M., Jonason, J.H., Loiselle, A.E., Kohn, A., Schwarz, E.M., Hilton, M.J., and O'Keefe, R.J. TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. J Bone Miner Res 25, 1784, 2010.
33. Li, W.Q., Dehnade, F., and Zafarullah, M. Oncostatin Minduced metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166, 3491, 2001.
34. Klatt, A.R., Klinger, G., Neumüller, O., Eidenmüller, B., Wagner, I., Achenbach, T., Aigner, T., and Bartnik, E. TAK1 downregulation reduces IL-1b induced expression of MMP13, MMP1 and TNF-Alpha. Biomed Pharmacother 60, 55, 2006.
35. Bau, B., Gebhard, P.M., Haag, J., Knorr, T., Bartnik, E., and Aigner, T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 46, 2648, 2002.
36. Rogerson, F.M., Chung, Y.M., Deutscher, M.E., Last, K., and Fosang, A.J. Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. Arthritis Rheum 62, 3365, 2010.
37. Mabrouk, M.E., Sylvester, J., and Zafarullah, M. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta 1773, 309, 2007.
38. Mithoefer, K., Williams, R.J., Warren, R.F., Potter, H.G., Spock, C.R., Jones, E.C., Wickiewicz, T.L., and Marx, R.G. Chondral resurfacing of articular cartilage defects in the knee with the microfracture technique. Surgical technique. J Bone Joint Surg Am 88 Suppl 1, 294, 2006.
39. Simon, T.M., and Jackson, D.W. Articular cartilage: Injury pathways and treatment options. Sports Med Arthrosc 14, 146, 2006.
40. Temenoff, J.S., and Mikos, A.G. Review: Tissue engineering for regeneration of articular cartilage. Biomaterials 21, 431, 2000.
41. Redman, S.N., Oldfield, S.F., and Archer, C.W. Current strategies for articular cartilage repair. Eur Cell Mater 9, 23, 2005.